Q4/2019 results revealed that Mauna Kea's top line grew 10% YoY to €7.4m for FY2019, despite weaker than expected Q4 sales of €1.7m (-20% YoY). Total FY2019 sales were largely driven by those to clinical customers, which represented 96% of total sales, and a 47% increase in consumable sales indicating high utilisation of the growing Cellvizio installed base. In-line with both ours and management's expectations, straight system sales decreased 14% YoY following the shift to a pay-per
03 Feb 2020
Driving utilisation in the clinic
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Driving utilisation in the clinic
Mauna Kea Technologies SA Class O (0P5I:LON) | 0 0 0.2% | Mkt Cap: 75.0m
- Published:
03 Feb 2020 - Author:
-
Pages:
5
Q4/2019 results revealed that Mauna Kea's top line grew 10% YoY to €7.4m for FY2019, despite weaker than expected Q4 sales of €1.7m (-20% YoY). Total FY2019 sales were largely driven by those to clinical customers, which represented 96% of total sales, and a 47% increase in consumable sales indicating high utilisation of the growing Cellvizio installed base. In-line with both ours and management's expectations, straight system sales decreased 14% YoY following the shift to a pay-per